Physician profile
Gregory S Wang
NPI 1871778068
$3,039.04
in general payments reported to CMS, 2019-2025
27 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $60.76 · 2022: $257 · 2023: $1,618 · 2024: $341 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719 · Travel and Lodging: $704 · Education: $71.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.95 |
| Travel and Lodging | $703.60 |
| Education | $71.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,231.61 | 2019-2025 | |
| Vifor Pharma, INC. | $179.33 | 2022-2024 | Korsuva, Veltassa |
| Akebia Therapeutics INC | $174.73 | 2019-2024 | Auryxia |
| Amgen INC. | $163.30 | 2023-2025 | Tavneos, Aranesp, Parsabiv |
| Opko Pharmaceuticals, LLC | $131.57 | 2022-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $129.86 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $129.44 | 2023-2025 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $127.68 | 2023-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $122.52 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $96.66 | 2022-2024 | Jesduvroq, Benlysta |
| Horizon Therapeutics Plc | $84.30 | 2022 | |
| Aurinia Pharma U.S., INC. | $78.60 | 2023-2024 | Lupkynis |
| Ardelyx, INC. | $57.69 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $38.18 | 2023 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $34.20 | 2023 | Velphoro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $33.62 | 2019 | |
| Travere Therapeutics, INC. | $28.64 | 2023 | |
| Genzyme Corporation | $28.48 | 2023 | |
| Argon Medical Devices, INC. | $28.32 | 2020 | |
| Cormedix INC. | $25.65 | 2024 | Defencath |
| Recor Medical INC | $22.49 | 2025 | Paradise Ultrasound Renal Denervation System |
| Alexion Pharmaceuticals, INC. | $21.37 | 2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $19.44 | 2025 | |
| Covidien Lp | $18.92 | 2019 | |
| Philips North America LLC | $18.57 | 2020 | |
| Amarin Pharma, INC. | $13.87 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,712.41 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.